Washington House Bill HB2204

Washington 2025-2026 Regular Session

• Introduced: 1/12/26
• Refer: 1/12/26

Caption

AN ACT Relating to the health technology assessment program;

Summary

HB2204 revises Washington’s health technology assessment program, which reviews medical technologies to determine whether they should be covered benefits in state health care programs. The bill directs the administrator, in consultation with participating agencies and the committee, to select technologies for review with priority given to technologies already recognized in Medicare coverage decisions or in nationally recognized expert treatment guidelines, including specialty physician and patient advocacy guidance. The bill also changes how technologies are reviewed and re-reviewed. It requires selected technologies to be assessed through a systematic, evidence-based review of safety, efficacy, and cost-effectiveness, using an evidence-based practice center or similar entity. For life-threatening or rare diseases, the committee must consider all applicable clinical trials and may consider expert input when randomized trials are impractical or unethical. Technologies already reviewed must be reconsidered at least every 18 months, and the committee may revisit prior decisions if new evidence emerges or if an interested party petitions for review.

Impact

HB2204 would amend the statutes governing the health technology assessment process and the criteria used by the health care authority and clinical committee when deciding whether a technology becomes a covered benefit in participating state health programs. It adds procedural requirements for selection, review, public notice, public comment, advisory input, and timelines for receipt and completion of assessments, while also requiring written explanations for adverse determinations. The bill would affect how state agencies evaluate medical technologies and could influence coverage decisions for Medicaid and other state-purchased health care programs, as well as the providers, manufacturers, patients, and advocacy groups involved in those determinations.

Sentiment

The bill text itself reflects a generally supportive, process-oriented approach focused on transparency, evidence standards, and regular re-evaluation of medical technologies. Because no committee transcripts or votes are provided, there is no recorded floor or committee sentiment to measure directly. Based on the structure of the bill, its tone appears aimed at strengthening and clarifying the assessment process rather than making a controversial substantive coverage expansion or restriction.

Contention

The main points of potential contention are the bill’s emphasis on evidence thresholds, the role of Medicare and expert guidelines in prioritizing technologies for review, and the balance between cost-effectiveness and access to newer treatments. Stakeholders who favor stricter evidence-based coverage rules may support the bill’s systematic review requirements, while patient advocates, specialty groups, or manufacturers could be concerned about delays, the weight given to cost-effectiveness, or the possibility that technologies with limited trial data—especially for rare or life-threatening conditions—could face more scrutiny. The bill also leaves room for disagreement over who gets to petition for review and how much discretion the committee should have when new evidence conflicts with prior determinations.